Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study

被引：26

作者：

Ito, Kentaro ^{[1
]}

Yamanaka, Takeharu ^{[2
]}

Hayashi, Hidetoshi ^{[3
]}

Hattori, Yoshihiro ^{[4
]}

Nishino, Kazumi ^{[5
]}

Kobayashi, Haruki ^{[6
]}

Oya, Yuko ^{[7
]}

Yokoyama, Toshihide ^{[8
]}

Seto, Takashi ^{[9
]}

Azuma, Koichi ^{[10
]}

Fukui, Tomoya ^{[11
]}

Kozuki, Toshiyuki ^{[12
]}

Nakamura, Atsushi ^{[13
]}

Tanaka, Kentaro ^{[14
]}

Hirano, Katsuya ^{[15
]}

Yokoi, Takashi ^{[16
]}

Daga, Haruko ^{[17
]}

Sakata, Shinya ^{[18
]}

Fujimoto, Daichi ^{[19
,26
]}

Mori, Masahide ^{[20
]}

Maeno, Ken ^{[21
]}

Aoki, Takuya ^{[22
]}

Tamura, Atsuhisa ^{[23
]}

Miura, Satoru ^{[24
]}

Watanabe, Satoshi ^{[25
]}

Akamatsu, Hiroaki ^{[26
]}

Hataji, Osamu ^{[1
]}

Suzuki, Kensuke ^{[27
]}

Hontsu, Shigeto ^{[28
]}

Azuma, Koji ^{[29
]}

Bessho, Akihiro ^{[30
]}

Kubo, Akihito ^{[31
]}

Okuno, Motoyasu ^{[32
]}

Nakagawa, Kazuhiko ^{[3
]}

Yamamoto, Nobuyuki ^{[26
]}

机构：

[1] Matsusaka Municipal Hosp, Resp Ctr, 1550 Tonomachi, Matsusaka City, Mie 5150073, Japan

[2] Yokohama City Univ, Sch Med, Dept Biostat, Kanazawa Ku, 22-2 Seto, Yokohama, Kanagawa 2360027, Japan

[3] Kindai Univ, Fac Med, Dept Med Oncol, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan

[4] Hyogo Canc Ctr, Dept Thorac Oncol, 13-70 Kitaoujicho, Akashi, Hyogo 6738558, Japan

[5] Osaka Int Canc Inst, Dept Thorac Oncol, Chuo Ku, 3-1-69 Otemae, Osaka, Osaka 5418567, Japan

[6] Shizuoka Canc Ctr, Div Thorac Oncol, 1007 Shimo Nagakubo, Nagaizumi, Shizuoka 4118777, Japan

[7] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan

[8] Kurashiki Cent Hosp, Dept Resp Med, 1-1-1 Miwa, Kurashiki, Okayama 7108602, Japan

[9] Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, 3-1-1 Minami Ku, Fukuoka, Fukuoka 8111395, Japan

[10] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[11] Kitasato Univ, Sch Med, Dept Resp Med, Minami Ku, 1-15-1 Kitazato, Sagamihara, Kanagawa 2520374, Japan

[12] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol, 160 Kou, Matsuyama, Ehime 7910280, Japan

[13] Sendai Kousei Hosp, Resp Med, Aoba Ku, 4-15 Hirose Cho, Sendai, Miyagi 9800873, Japan

[14] Kyushu Univ, Grad Sch Med Sci, Chest Dis Res Inst, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan

[15] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, 2-17-77 Higashinaniwacho, Amagashiki, Hyogo 6608550, Japan

[16] Hyogo Coll Med, Dept Thorac Oncol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan

[17] Osaka City Gen Hosp, Dept Med Oncol, Miyakojima Ku, 2-13-22 Miyakojima Hondori, Osaka 5340021, Japan

[18] Kumamoto Univ Hosp, Dept Resp Med, Chuo Ku, 1-1-1 Honjo, Kumamoto, Kumamoto 8608556, Japan

[19] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Chuo Ku, 2-1-1 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan

[20] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, 5-1-1 Toneyama, Toyonaka, Osaka 5608552, Japan

[21] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan

[22] Tokai Univ, Sch Med, Dept Internal Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan

[23] Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, 3-1-1 Takeoka, Tokyo 2048585, Japan

[24] Niigata Canc Ctr Hosp, Dept Internal Med, Chuo Ku, 2-15-3 Kawagishi Cho, Niigata, Niigata 9518566, Japan

[25] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Chuo Ku, 1-757 Asahimachidori, Niigata 9518510, Japan

[26] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama 8111, Japan

[27] Toyama Prefectural Cent Hosp, Internal Med, 2-2-78 Nishinagae, Toyama, Toyama 9308550, Japan

[28] Nara Med Univ, Dept Resp Med, 840 Shijo Cho, Kashihara, Nara 6348522, Japan

[29] Itami City Hosp, Dept Internal Med, Div Resp, 1-100 Koyaike, Itami, Hyogo 6648540, Japan

[30] Japanese Red Cross Okayama Hosp, Dept Resp Med, Kita Ku, 2-1-1 Aoe, Okayama, Okayama 7008607, Japan

[31] Aichi Med Univ, Sch Med, Div Resp Med & Allergol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan

[32] Okazaki City Hosp, Dept Resp Med, 3-1 Kouryuuji Town Gosyoai, Okazaki, Aichi 4448553, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 145卷

关键词：

Anaplastic lymphoma kinase; Non-small cell lung cancer; Crizotinib; Alectinib; Sequential therapy; Real-world data; OPEN-LABEL; SURVIVAL;

D O I：

10.1016/j.ejca.2020.12.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The data of sequential therapy of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in clinical practice have been limited. Methods: We reviewed the clinical data of patients with ALK-rearranged non-small cell lung cancer who received crizotinib (CRZ) or alectinib (ALEC) between May 2012 and December 2016. Patients were divided into two groups based on the first-administered ALK-TKI, the CRZ or ALEC group. The combined time-to-treatment failure (TTF) was defined as the sum of the 'TTF of CRZ' plus the 'TTF of ALEC' if patients were treated with CRZ followed by ALEC in the CRZ group. The primary end-point is the comparison between the combined TTF and the TTF of ALEC in the ALEC group. Results: Of 864 patients enrolled from 61 institutions, 840 patients were analysed. There were 535 of 305 patients in the CRZ/ALEC groups. The combined TTF in the CRZ group was significantly longer than TTF in the ALEC group (median, 34.4 versus 27.2 months; hazard ratio [HR], 0.709; P = 0.0044). However, there was no significant difference in overall survival (OS) between the patients who received ALEC after CRZ in the CRZ group and the patients in the ALEC group (median, 88.4 months versus. not reached; HR, 1.048; P = 0.7770). In the whole population, the CRZ group had a significantly shorter OS than the ALEC group (median, 53.6 months versus not reached; HR, 1.821, P < 0.0001). Conclusion: The combined TTF in the CRZ group was significantly longer than the TTF in the ALEC group; however, OS benefit of sequential therapy against ALEC as the first ALK-TKI was not shown. (C) 2021 Elsevier Ltd. All rights reserved.

引用

页码：183 / 193

页数：11

共 17 条

[1] Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study [J].

Camidge, D. Ross ;

Dziadziuszko, Rafal ;

Peters, Solange ;

Mok, Tony ;

Noe, Johannes ;

Nowicka, Malgorzata ;

Gadgeel, Shirish M. ;

Cheema, Parneet ;

Pavlakis, Nick ;

de Marinis, Filippo ;

Cho, Byoung Chul ;

Zhang, Li ;

Moro-Sibilot, Denis ;

Liu, Ting ;

Bordogna, Walter ;

Balas, Bogdana ;

Mueller, Barbara ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) :1233-1243

[2] Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma [J].

Christopoulos, P. ;

Kirchner, M. ;

Bozorgmehr, F. ;

Endris, V. ;

Elsayed, M. ;

Budczies, J. ;

Ristau, J. ;

Penzel, R. ;

Herth, F. J. ;

Heussel, C. P. ;

Eichhorn, M. ;

Muley, T. ;

Meister, M. ;

Fischer, J. R. ;

Rieken, S. ;

Lasitschka, F. ;

Bischoff, H. ;

Sotillo, R. ;

Schirmacher, P. ;

Thomas, M. ;

Stenzinger, A. .

INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (01) :190-199

[3]

Christopoulos Petros, 2019, Oncotarget, V10, P3093, DOI 10.18632/oncotarget.26886

[4] EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer [J].

Christopoulos, Petros ;

Endris, Volker ;

Bozorgmehr, Farastuk ;

Elsayed, Mei ;

Kirchner, Martina ;

Ristau, Jonas ;

Buchhalter, Ivo ;

Penzel, Roland ;

Herth, Felix J. ;

Heussel, Claus P. ;

Eichhorn, Martin ;

Muley, Thomas ;

Meister, Michael ;

Fischer, Juergen R. ;

Rieken, Stefan ;

Warth, Arne ;

Bischoff, Helge ;

Schirmacher, Peter ;

Stenzinger, Albrecht ;

Thomas, Michael .

INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (12) :2589-2598

[5] NCCN Guidelines® Insights Non- Small Cell Lung Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines [J].

Ettinger, David S. ;

Aisner, Dara L. ;

Wood, Douglas E. ;

Akerley, Wallace ;

Bauman, Jessica ;

Chang, Joe Y. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

Dilling, Thomas J. ;

Dobelbower, Michael ;

Govindan, Ramaswamy ;

Gubens, Matthew A. ;

Hennon, Mark ;

Horn, Leora ;

Lackner, Rudy P. ;

Lanuti, Michael ;

Leal, Ticiana A. ;

Lilenbaum, Rogerio ;

Lin, Jules ;

Loo, Billy W., Jr. ;

Martins, Renato ;

Otterson, Gregory A. ;

Sandip, P. ;

Reckamp, Karen ;

Riely, Gregory J. ;

Schild, Steven E. ;

Shapiro, Theresa A. ;

Stevenson, James ;

Swanson, Scott J. ;

Tauer, Kurt ;

Yang, Stephen C. ;

Gregory, Kristina ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (07) :807-821

[6] Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK [J].

Fontana, Diletta ;

Ceccon, Monica ;

Gambacorti-Passerini, Carlo ;

Mologni, Luca .

CANCER MEDICINE, 2015, 4 (07) :953-965

[7] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [J].

Gainor, Justin F. ;

Dardaei, Leila ;

Yoda, Satoshi ;

Friboulet, Luc ;

Leshchiner, Ignaty ;

Katayama, Ryohei ;

Dagogo-Jack, Ibiayi ;

Gadgeel, Shirish ;

Schultz, Katherine ;

Singh, Manrose ;

Chin, Emily ;

Parks, Melissa ;

Lee, Dana ;

DiCecca, Richard H. ;

Lockerman, Elizabeth ;

Huynh, Tiffany ;

Logan, Jennifer ;

Ritterhouse, Lauren L. ;

Le, Long P. ;

Muniappan, Ashok ;

Digumarthy, Subba ;

Channick, Colleen ;

Keyes, Colleen ;

Getz, Gad ;

Dias-Santagata, Dora ;

Heist, Rebecca S. ;

Lennerz, Jochen ;

Sequist, Lecia V. ;

Benes, Cyril H. ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. ;

Shaw, Alice T. .

CANCER DISCOVERY, 2016, 6 (10) :1118-1133

[8] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial [J].

Hida, Toyoaki ;

Nokihara, Hiroshi ;

Kondo, Masashi ;

Kim, Young Hak ;

Azuma, Koichi ;

Seto, Takashi ;

Takiguchi, Yuichi ;

Nishio, Makoto ;

Yoshioka, Hiroshige ;

Imamura, Fumio ;

Hotta, Katsuyuki ;

Watanabe, Satoshi ;

Goto, Koichi ;

Satouchi, Miyako ;

Kozuki, Toshiyuki ;

Shukuya, Takehito ;

Nakagawa, Kazuhiko ;

Mitsudomi, Tetsuya ;

Yamamoto, Nobuyuki ;

Asakawa, Takashi ;

Asabe, Ryoichi ;

Tanaka, Tomohiro ;

Tamura, Tomohide .

LANCET, 2017, 390 (10089) :29-39

[9] Sequential Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study [J].

Ito, Kentaro ;

Hataji, Osamu ;

Kobayashi, Hiroyasu ;

Fujiwara, Atsushi ;

Yoshida, Masamichi ;

D'Alessandro-Gabazza, Corina N. ;

Itani, Hidetoshi ;

Tanigawa, Motoaki ;

Ikeda, Takuya ;

Fujiwara, Kentaro ;

Fujimoto, Hajime ;

Kobayashi, Tetsu ;

Gabazza, Esteban C. ;

Taguchi, Osamu ;

Yamamoto, Nobuyuki .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :390-396

[10] Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer [J].

Kron, A. ;

Alidousty, C. ;

Scheffler, M. ;

Merkelbach-Bruse, S. ;

Seidel, D. ;

Riedel, R. ;

Ihle, M. A. ;

Michels, S. ;

Nogova, L. ;

Fassunke, J. ;

Heydt, C. ;

Kron, F. ;

Ueckeroth, F. ;

Serke, M. ;

Krueger, S. ;

Grohe, C. ;

Koschel, D. ;

Benedikter, J. ;

Kaminsky, B. ;

Schaaf, B. ;

Braess, J. ;

Sebastian, M. ;

Kambartel, K. -O. ;

Thomas, R. ;

Zander, T. ;

Schultheis, A. M. ;

Buettner, R. ;

Wolf, J. .

ANNALS OF ONCOLOGY, 2018, 29 (10) :2068-2075

← 1 2 →